Medicine
Ctexli 250 mg tablet
Ctexli 250 mg tablet is a prescription medicine containing Chenodiol for oral use, marketed by Mirum Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store CTEXLI at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C…
Key facts
- Active ingredient (INN)
- Chenodiol
- Brand
- Ctexli
- Strength
- 250 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 100 tablets
- Marketing authorisation holder
- Mirum Pharmaceuticals
- Manufacturer
- Mirum Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store CTEXLI at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A05AA01 Chenodiol
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 4 April 2025
- Identifiers
- RxCUI 618469, 2710422DailyMed set ID 015384e7-4ac5-4782-a309-e40cd1421c5bNDC 79378-310Application NDA219488
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet, film coated in 1 bottle | 79378-310-90 | Mirum Pharmaceuticals | 4 April 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 28 July 1983 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Chenodiol 250 mg tablet.
Clinical summary
Chenodiol is a bile acid indicated for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. It is available as tablets for oral use. MedsAcross supplies Chenodiol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ChenodiolFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- CTEXLI prescribing information (Mirum Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Ctexli 250 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.